JP2015510882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510882A5 JP2015510882A5 JP2014560955A JP2014560955A JP2015510882A5 JP 2015510882 A5 JP2015510882 A5 JP 2015510882A5 JP 2014560955 A JP2014560955 A JP 2014560955A JP 2014560955 A JP2014560955 A JP 2014560955A JP 2015510882 A5 JP2015510882 A5 JP 2015510882A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 4
- 229940068968 polysorbate 80 Drugs 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- 239000007979 citrate buffer Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 239000003186 pharmaceutical solution Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607671P | 2012-03-07 | 2012-03-07 | |
| US61/607,671 | 2012-03-07 | ||
| PCT/US2013/028516 WO2013134052A1 (en) | 2012-03-07 | 2013-03-01 | Il-17 antibody formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510882A JP2015510882A (ja) | 2015-04-13 |
| JP2015510882A5 true JP2015510882A5 (OSRAM) | 2016-03-24 |
| JP6117252B2 JP6117252B2 (ja) | 2017-04-19 |
Family
ID=47892018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560955A Active JP6117252B2 (ja) | 2012-03-07 | 2013-03-01 | Ｉｌ−１７抗体製剤 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9376491B2 (OSRAM) |
| EP (2) | EP2822590B1 (OSRAM) |
| JP (1) | JP6117252B2 (OSRAM) |
| KR (1) | KR101653082B1 (OSRAM) |
| CN (1) | CN104159612B (OSRAM) |
| AU (1) | AU2013230490B2 (OSRAM) |
| BR (1) | BR112014021308B1 (OSRAM) |
| CA (1) | CA2866128C (OSRAM) |
| CL (1) | CL2014002204A1 (OSRAM) |
| CY (1) | CY1118393T1 (OSRAM) |
| DK (1) | DK2822590T3 (OSRAM) |
| EA (1) | EA030742B1 (OSRAM) |
| EC (1) | ECSP14017562A (OSRAM) |
| ES (1) | ES2610707T3 (OSRAM) |
| HR (1) | HRP20161604T1 (OSRAM) |
| HU (1) | HUE031290T2 (OSRAM) |
| IL (1) | IL234053B (OSRAM) |
| LT (1) | LT2822590T (OSRAM) |
| MA (1) | MA37317B1 (OSRAM) |
| ME (1) | ME02565B (OSRAM) |
| MX (1) | MX362191B (OSRAM) |
| MY (1) | MY167233A (OSRAM) |
| NZ (1) | NZ627648A (OSRAM) |
| PE (1) | PE20142275A1 (OSRAM) |
| PH (1) | PH12014501985B1 (OSRAM) |
| PL (1) | PL2822590T3 (OSRAM) |
| PT (1) | PT2822590T (OSRAM) |
| RS (1) | RS55417B1 (OSRAM) |
| SG (1) | SG11201404491XA (OSRAM) |
| SI (1) | SI2822590T1 (OSRAM) |
| TN (1) | TN2014000341A1 (OSRAM) |
| UA (1) | UA114620C2 (OSRAM) |
| WO (1) | WO2013134052A1 (OSRAM) |
| ZA (1) | ZA201405654B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CA3063324A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| WO2019027828A1 (en) * | 2017-08-04 | 2019-02-07 | Eli Lilly And Company | DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES |
| CN111032691A (zh) * | 2017-08-23 | 2020-04-17 | 伊莱利利公司 | 生殖器银屑病的治疗 |
| MX2017016884A (es) * | 2017-12-19 | 2019-06-20 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina anti-tnfa. |
| EP3888678A4 (en) * | 2018-11-29 | 2022-02-16 | Harbour Biomed Therapeutics Limited | PREPARATION OF AN ANTI-PD-L1 ANTIBODY |
| CN120241997A (zh) * | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| WO2022135395A1 (zh) * | 2020-12-22 | 2022-06-30 | 百奥泰生物制药股份有限公司 | 稳定的抗体制剂及其制备方法和应用 |
| CN119147687B (zh) * | 2024-11-11 | 2025-03-14 | 智翔（上海）医药科技有限公司 | 用于抗白介素17a抗体质量检测的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2672221T3 (es) * | 2005-12-13 | 2018-06-13 | Eli Lilly And Company | Anticuerpos anti IL-17 |
| JP5410985B2 (ja) * | 2006-12-05 | 2014-02-05 | クルセル ホランド ベー ヴェー | 液体抗狂犬病抗体製剤 |
| WO2011088120A1 (en) * | 2010-01-15 | 2011-07-21 | Amgen Inc. | Antibody formulation and therapeutic regimens |
-
2013
- 2013-03-01 SI SI201330364A patent/SI2822590T1/sl unknown
- 2013-03-01 KR KR1020147024733A patent/KR101653082B1/ko active Active
- 2013-03-01 ES ES13710214.1T patent/ES2610707T3/es active Active
- 2013-03-01 MX MX2014010710A patent/MX362191B/es active IP Right Grant
- 2013-03-01 EA EA201491471A patent/EA030742B1/ru not_active IP Right Cessation
- 2013-03-01 UA UAA201409450A patent/UA114620C2/uk unknown
- 2013-03-01 NZ NZ627648A patent/NZ627648A/en unknown
- 2013-03-01 HR HRP20161604TT patent/HRP20161604T1/hr unknown
- 2013-03-01 CN CN201380012452.5A patent/CN104159612B/zh active Active
- 2013-03-01 WO PCT/US2013/028516 patent/WO2013134052A1/en not_active Ceased
- 2013-03-01 RS RS20160994A patent/RS55417B1/sr unknown
- 2013-03-01 US US14/379,755 patent/US9376491B2/en active Active
- 2013-03-01 AU AU2013230490A patent/AU2013230490B2/en active Active
- 2013-03-01 EP EP13710214.1A patent/EP2822590B1/en active Active
- 2013-03-01 MY MYPI2014702489A patent/MY167233A/en unknown
- 2013-03-01 DK DK13710214.1T patent/DK2822590T3/en active
- 2013-03-01 CA CA2866128A patent/CA2866128C/en active Active
- 2013-03-01 EP EP16195503.4A patent/EP3156073A1/en not_active Withdrawn
- 2013-03-01 ME MEP-2016-259A patent/ME02565B/me unknown
- 2013-03-01 LT LTEP13710214.1T patent/LT2822590T/lt unknown
- 2013-03-01 JP JP2014560955A patent/JP6117252B2/ja active Active
- 2013-03-01 BR BR112014021308-9A patent/BR112014021308B1/pt active IP Right Grant
- 2013-03-01 PL PL13710214T patent/PL2822590T3/pl unknown
- 2013-03-01 PT PT137102141T patent/PT2822590T/pt unknown
- 2013-03-01 HU HUE13710214A patent/HUE031290T2/hu unknown
- 2013-03-01 PE PE2014001367A patent/PE20142275A1/es active IP Right Grant
- 2013-03-01 SG SG11201404491XA patent/SG11201404491XA/en unknown
-
2014
- 2014-07-30 ZA ZA2014/05654A patent/ZA201405654B/en unknown
- 2014-08-06 TN TNP2014000341A patent/TN2014000341A1/fr unknown
- 2014-08-11 IL IL234053A patent/IL234053B/en active IP Right Grant
- 2014-08-19 CL CL2014002204A patent/CL2014002204A1/es unknown
- 2014-09-02 MA MA37317A patent/MA37317B1/fr unknown
- 2014-09-05 EC ECIEPI201417562A patent/ECSP14017562A/es unknown
- 2014-09-05 PH PH12014501985A patent/PH12014501985B1/en unknown
-
2016
- 2016-06-10 US US15/178,583 patent/US9845353B2/en active Active
- 2016-12-23 CY CY20161101339T patent/CY1118393T1/el unknown
-
2017
- 2017-11-10 US US15/808,939 patent/US10472416B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510882A5 (OSRAM) | ||
| HRP20161604T1 (hr) | Formulacija protutijela protiv il-17 | |
| JP2019504086A5 (OSRAM) | ||
| FI3310809T3 (fi) | Anti-cgrp-vasta-aineformulaatio | |
| JP2018127467A5 (OSRAM) | ||
| JP2013543505A5 (OSRAM) | ||
| JP2014169326A5 (OSRAM) | ||
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| JP2013517277A5 (OSRAM) | ||
| JP2011219478A5 (OSRAM) | ||
| EA201891154A1 (ru) | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей | |
| JP2013520405A5 (OSRAM) | ||
| JP2018510132A5 (OSRAM) | ||
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JP2015527402A5 (OSRAM) | ||
| JP2015526440A5 (OSRAM) | ||
| HRP20251174T1 (hr) | Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| EA201991704A3 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| JP2016516074A5 (OSRAM) | ||
| JP2014516924A5 (OSRAM) | ||
| RU2011142183A (ru) | Средство для лечения ревматоидного артрита | |
| JP2012532619A5 (OSRAM) | ||
| JP2014513722A5 (OSRAM) |